WESTBOROUGH, Mass., March 14, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced upcoming presentations at the 6th Ocular Diseases and Drug Development Conference, the 72nd Annual Meeting of the American Academy of Dermatology ("AAD") and the Keystone Symposia Meeting, Fibrosis: From Bench to Bedside.
6th Ocular Diseases and Drug Development Conference
On Thursday, March 20, 2014 at 10:55 a.m. PDT, Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals will be presenting an overview on the potential of RNAi therapy in ocular disease. The Ocular Diseases and Drug Discovery Conference promotes the discovery of ocular disease drug development by bringing together leading scientists, researchers and experts to discuss and collaborate on the latest research and development, safety assessment, regulatory issues and drugs in development for combating and curing ocular diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and other ocular diseases. This conference will take place March 20-21, 2014 in San Diego, CA. Dr. Cauwenbergh's presentation will be available on the Company's website.
72nd Annual Meeting of the American Academy of Dermatology
The American Academy of Dermatology supports the highest-quality patient care by developing and presenting information that enhances continuing education in dermatology. AAD meetings offer the latest on the diagnosis, prevention, and treatment of dermatologic disease from the foremost experts in the field. RXi's senior management team members will be presenting three poster presentations on March 22, 2014. Poster 8326 "Reduction of Connective Tissue Growth Factor (CTGF) by an RNA Interference (RNAi) Mechanism as a Potential Treatment for Fibrotic Skin Indications" will be presented by Dr. Pamela Pavco, RXi's Chief Development Officer at 4:10 p.m. MDT. Poster 8225 "RXI-109 Reduces a Key Component of Dermal Scarring, Connective Tissue Growth Factor (CTGF) mRNA, in a Multi-dose Phase 1 Clinical Trial" will be presented by Dr. Lyn Libertine, Vice President Medical Affairs and Safety Assessment for RXi, at 4:15 p.m. MDT. Lastly, Poster 8214 "The RNAi Compound RXI-109 Reduces Connective Tissue Growth Factor (CTGF), a Key Component of Dermal Scarring, at Incision Sites in a First-in-Human Phase 1 Clinical Trial" will be presented by Dr. Pavco at 4:25 p.m. MDT. All three posters will be available on the Company's website.
Keystone Symposia Meeting, Fibrosis: From Bench to Bedside
RXi's Manager of Platform Technology, Dr. James Cardia will present a poster titled "Reduction of Connective Tissue Growth Factor (CTGF) by an RNA Interference (RNAi) Mechanism as a Potential Treatment for Fibrotic Skin Indications" on March 26, 2014 from 7:30-10:00 p.m. MDT. The mission of the Keystone Symposia is to serve as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops held at venues that create an environment conducive to information exchange, a generation of new ideas and acceleration of applications that benefit society. This Fibrosis Symposia brings together researchers, with an interest in fibrosis, aiming to bridge the gap between basic research and clinical findings and pharmaceutical development and will take place March 23‑28, 2014, at the Keystone Resort in Keystone, Colorado. Dr. Cardia's presentation will be available on the Company's website.
RXi Pharmaceuticals' first clinical program involves RXI‑109, a self-delivering RNAi compound (sd‑rxRNA®) developed for the reduction of dermal scarring. RXI‑109 is designed to reduce the expression of connective tissue growth factor ("CTGF"), a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin. The first clinical trials with RXI‑109 showed excellent safety and tolerability with ascending single and multiple doses, as well as dose dependent effects on the CTGF protein and on the mRNA that controls production of this protein.
RXi's sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and antisense technologies. This allows sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012. For more information, please visit www.rxipharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
RXi Pharmaceuticals Corporation Tamara McGrillen, 508-929-3646 firstname.lastname@example.org
SOURCE RXi Pharmaceuticals Corporation